Country/Region: South Korea
PE Guidelines

Pharmaceutical Economic Evaluation Guidelines (January 2006)
PDF in Korean

PE Guidelines Source:

Health Insurance Review & Assessment Service

Additional Information:

PE Guideline Key Features – in Progress

Information up to date as of Tuesday, May 17, 2011

PE Guidelines Key Features:

Key Features:  
Title and year of the document
Pharmaceutical Economic Evaluation Guidelines (January 2006) 
Affiliation of authors
Purpose of the document
Standard reporting format included
Target audience of funding/ author's interests
Target population
Subgroup analysis
Choice of comparator
Time horizon
Assumptions required
Preferred analytical technique
Costs to be included
Source of costs
Systematic review of evidences
Preference for effectiveness over efficacy
Preferred outcome measure
Preferred method to derive utility
Equity issues stated
Discounting costs
Discounting outcomes
Sensitivity analysis-parameters and range
Sensitivity analysis-methods
Presenting results
Incremental analysis
Total costs vs effectiveness (cost/effectiveness ratio)
Portability of results (Generalizability)
Financial impact analysis
Mandatory or recommended or voluntary

Country Selection Page | PE Guidelines Index Page